The Journey to Serve 1 Million Cancer Patients with Oncotype DX Tests
Making Cancer Care Smarter
As the world's leading provider of genomic-based diagnostic tests, we're committed to making cancer care smarter with our Oncotype IQ Genomic Intelligence Platform. This expanding suite of tissue- and liquid-based tests answers specific questions across the patient journey—from diagnosis through treatment and ongoing cancer management-through a single, trusted source easily accessed via our secure web-based platform for physicians to interpret and share results with patients.
Oncology and Urology Channels
 |
Oncotype DX
Our flagship line of gene expression tests has been used to guide treatment decisions for more than 1 million breast, colon, and prostate cancer patients worldwide.
|
Oncotype IQ Platform Evolution
Launched recently in collaboration agreement with Epic Sciences, this liquid biopsy-based assay helps men with metastatic prostate cancer determine the most effective, life-sustaining therapy. Performed in Epic Science's CLIA-certified laboratory, the test will detect the expression of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells. Learn more
The Road Ahead
Looking ahead, we will continue to expand our Oncotype IQ platform through internal development programs and strategic partnerships, all with the goal of making cancer care smarter.